Hero background

Around the World.
And Back.

Map
Hero background
Sixteen clinical protocols

Open for Recruitment

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer
Idris Bahce M.D., Ph.D. I Amsterdam UMC

This PET imaging trial will compare two promising T cell PET tracers alongside the pathological analysis of the resected tumor. Following chemo-immunotherapy, NSCLC patients will undergo two PET scans shortly before their surgery.

[18F]F-AraG PET imaging of Non Small Cell Lung Cancer patients undergoing checkpoint inhibitor immunotherapy
Yuji Nakamoto M.D. Ph.D. and Tomomi W Nobashi M.D. I Kyoto University

This study explores tumoral uptake of [18F]F-AraG and its association with the treatment effect of immune checkpoint inhibitors for stage 4 NSCLC patients. [18F]F-AraG PET/CT scanning will be performed twice per patient, pre and post start of immunotherapy. The uptake difference in tumor and associated lymphoid organs will be considered for the analysis, as well as the correlation with the expression of CD8, PD-1 and Treg markers in immunohistochemistry. CellSight is providing [18F]F-AraG precursor free of charge.

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Muhammad Furqan M.D. I Holden Comprehensive Cancer Center

This pilot study uses [18F]F-AraG PET imaging to evaluate the immunological response to inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. 

Test-retest Evaluation of [18F]F-AraG PET
John Sunderland Ph.D. and Muhammad Furqan M.D. I Holden Comprehensive Cancer Center

This pilot study aims to evaluate the test-retest variability of [18F]F-AraG-PET imaging in patients with advanced NSCLC tumors.

A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer (SHARP)
Idris Bahce M.D., Ph.D. I Amsterdam UMC

The aim of the SHARP trial is to investigate changes in [18F]F-AraG uptake following Anti-PD-1 therapy in patients with non-small cell lung cancer (NSCLC).

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
Shivaani Kummar M.D. , Erik Mittra M.D. and Carina Mari Aparici M.D. I Oregon Health and Science University and Stanford University

In this study, patients with advanced solid tumors will undergo [18F]F-AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
Simon R Cherry Ph.D. I University of California, Davis

In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body PET/CT scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images.

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-Small Cell Lung Cancer (NSCLC)
Millie Das M.D., Minal Vasanawala M.D., and Deepti Behl M.D. I Palo Alto Veteran’s Affairs and Sutter Medical Center

This is a pilot study using [18F]F-AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites.

Imaging Immune Activation in COVID-19
Timothy Henrich M.D. I University of California, San Francisco

This is a single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19.

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
David Miklos M.D., Ph.D. I Standford University

This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.

[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer (ATTAIN)
Idris Bahce M.D., Ph.D. I Amsterdam UMC

The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of [18F]F-AraG by performing a full kinetic modelling, assess test-retest (TRT) variability and to correlate the tumor tracer uptake with the pathological assessment.

Imaging Immune Activation in HIV by PET-MR
Timothy J Henrich M.D. I University of California, San Francisco

This study involves one intravenous microdose of [18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer.

Past Studies
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
Martin Pomper M.D., Ph.D. I Johns Hopkins University

This is a prospective clinical trial in patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if [18F]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response levels for NSCLC patients who will receive a cancer immunotherapy regimen.

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
Diwakar Davar M.D., M.Sc. I University of Pittsburgh Medical Center

The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer
Dustin Osborne Ph.D. I University of Tennessee

This study is to assess the biodistribution and kinetics of [18F]F-AraG in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy.

Detection of Graft Versus Host Disease With [18F]F-AraG
Sanjiv Gambhir M.D., Ph.D. I Stanford University

This study determines the utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD.

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
Lawrence Fong M.D. I University of California, San Francisco

This phase II trial studies how well [18F]F-AraG PET/MR imaging works in measuring clinical response to atezolizumab or patients with cancer receiving standard of care Anti-PD-1/L1.

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A. Dimitrios Colevas M.D. I Stanford University

This is a cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Two whole body PET/CT images with [18F]F-AraG, blood samples, and tissue biopsies will be collected from patients.

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
Robert R Flavell M.D., Ph.D. I UCSF Department of Radiology and Biomedical Imaging

This is a Phase 1 study is to visualize biodistribution of [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
Henry Vanbrocklin Ph.D. I University of California, San Francisco

The goal of this study is to visualize biodistribution of [18F]F-AraG through time in healthy human volunteers.